EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

HAW PAR CORP LTD (H02) fair value: what the stock is really worth

We calculate from audited financials what HAW PAR CORP LTD is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · SG · ISIN SG1D25001158

HP Broad data Sep 19, 2026

HAW PAR CORP LTD

H02 · SG

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value 8.53 SGD · Strongly overvalued (−36%)
Quality 70/100
!Expensive Growth (revenue 5y +15.7 %/yr)
Highly profitable · 115.4% net margin (TTM)
Low debt · generates free cash flow
·3.02% dividend yield
!Mixed vs. peers (7/14)
!Weak on past: 25 out of 100

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

18.05 SGD 7.35 SGD Fair Value 8.53 SGD Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 19, 2026.

How to read this chart

60‑month range 7.35 SGD – 18.05 SGD · fair‑value band 7.24 SGD – 10.36 SGD · the 13.26 SGD price screens above the 8.53 SGD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 19, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Haw Par Corporation Limited, together with its subsidiaries, manufactures, markets, and trades in healthcare products in Singapore, The Association of Southeast Asian Nations countries, other Asian countries, and internationally.

Show more

Haw Par Corporation Limited, together with its subsidiaries, manufactures, markets, and trades in healthcare products in Singapore, The Association of Southeast Asian Nations countries, other Asian countries, and internationally. It manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands; and invests in quoted securities. The company also owns and leases various investment properties. In addition, it provides family and tourist oriented leisure activities primarily in the form of oceanariums. Further, the company is involved in the property development; and owning and letting properties; letting out of office spaces; and management support services. Haw Par Corporation Limited was incorporated in 1969 and is based in Singapore.

Stock analysis

HAW PAR CORP LTD (H02) currently trades at 13.26 SGD, while our model-based Fair Value estimate is 8.53 SGD, implying the stock looks roughly 55.4% overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of 22.58 SGD per share, and 8 of the 24 models we run sit above the 13.26 SGD price.

Bear case: the Economic Profit group reads lowest at 6.06 SGD, and 16 of the 24 models stay below the price. Evidence for this calculation is high.

Scenario range: 7.24 SGD (bear) to 10.36 SGD (bull), the price of 13.26 SGD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

HAW PAR CORP LTD reported revenue of 230M SGD in FY2025 versus 141M SGD in FY2021, a compound +13.0%/yr. Reported net income was 265M SGD in FY2025, compounding +24.6%/yr from FY2021.

Key figures

Market cap 3.5B SGD (≈ $2.8B) · P/E ratio 11.1 · P/S ratio 12.8 · EPS (TTM) 1.20 SGD · Dividend yield 3.0% · Net margin 115% · Return on equity 6.3% · Return on assets (EBIT) 1.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 27% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −36%, H02 screens richer than that median.

Fair Value models

Bear 7.24 SGD Fair Value 8.53 SGD Bull 10.36 SGD
Model Each model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.5764 SGD per share) are deliberately not added. Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence Evidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF 6.00 SGD 7.27 SGD 9.09 SGD 82
Growth DCF 6.05 SGD 7.18 SGD 8.72 SGD 80
Owner Earnings 16.24 SGD 22.48 SGD 31.39 SGD 77
All 24 models by family
DCF Models
FCF DCF 6.00 SGD 7.27 SGD 9.09 SGD 82
Owner Earnings 16.24 SGD 22.48 SGD 31.39 SGD 77
5Y Revenue Exit 5.65 SGD 6.84 SGD 8.34 SGD 74
5Y EBITDA Exit 6.29 SGD 8.02 SGD 10.01 SGD 77
5Y P/E Exit 15.41 SGD 24.78 SGD 34.53 SGD 70
10Y Revenue Exit 5.69 SGD 6.79 SGD 8.20 SGD 68
10Y EBITDA Exit 6.15 SGD 7.58 SGD 9.43 SGD 70
10Y P/E Exit 11.80 SGD 18.85 SGD 27.43 SGD 63
Earnings-Based
Graham-Dodd 8.15 SGD 23.19 SGD 30.56 SGD 65
Lynch FV 4.73 SGD 6.76 SGD 8.79 SGD 61
PEG = 1.0 4.73 SGD 6.76 SGD 8.79 SGD 57
EPV 5.69 SGD 6.06 SGD 6.37 SGD 74
Multiples
P/E Multiple 19.79 SGD 26.38 SGD 32.98 SGD 63
P/S Multiple 2.73 SGD 3.64 SGD 4.54 SGD 58
P/B Multiple 15.29 SGD 20.39 SGD 25.48 SGD 55
EV/EBIT 7.24 SGD 8.53 SGD 9.82 SGD 66
EV/EBITDA 6.86 SGD 8.02 SGD 9.18 SGD 67
EV/Revenue 5.56 SGD 6.49 SGD 7.43 SGD 54
Asset-Based
NCAV (Graham) 9.69 SGD 12.99 SGD 19.38 SGD 54
Growth DCF
Growth DCF 6.05 SGD 7.18 SGD 8.72 SGD 80
Rev-Margin DCF 5.65 SGD 6.86 SGD 8.24 SGD 74
Economic Profit
Residual Income 15.12 SGD 15.56 SGD 15.64 SGD 76
ROIC Compounder 5.69 SGD 6.06 SGD 6.37 SGD 72
Growth Earnings
Growth-Adj P/E 15.81 SGD 22.58 SGD 29.35 SGD 67

Open the full fair value analysis →

Notify me when H02 reaches fair value

Put H02 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 70/100

Of which business quality 68 · Market factors (momentum, volatility) 46

Profitability 37
Margins and returns on capital today
Quality Growth 53
Are margins and returns improving?
Cashflow 70
Earnings quality: real cash, not paper profit
Fin. Strength 92
Balance sheet, leverage, solvency risk
Investment 78
Disciplined investing over empire-building
Low Volatility 93
Calm price path (market factor)
Momentum 29
Price trend over the last 3–12 months (market factor)
52W Momentum 24
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality Growth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−6.1%
Revenue growth 3 years Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.1%
Revenue growth 5 years Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.7%
Revenue growth 12 years Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.1%
What shareholders gained per year (last 5 years) What the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+20.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+17.2%
Dividend (yield on the price)3.0%
Profit margin 2020 to 2025 Operating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 29%

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes This turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+20.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.

H02 screens 55% overvalued. Compare with Eli Lilly and Company →

Compare HAW PAR CORP LTD with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 73 stocks

Beats the industry median on 7/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 70 · Above median
Fair Value upside −39% · Below median
Profitability
Return on equity (TTM) 6% · Below median
Return on assets 1% · Bottom 25%
Net margin (TTM) 115% · Top 25%
Operating margin (TTM) 33% · Top 25%
Growth and dividend
Revenue growth −18% · Bottom 25%
Dividend yield (TTM) 3.0% · Above median
Balance sheet
Debt / equity 0.01× · Below median

Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper

P/E (TTM) 11.1× · Cheapest 25%
P/B 0.65× · Cheapest 25%
P/S (TTM) 12.11× · Priciest 25%
P/FCF 50.6× · Priciest 25%
EV/EBITDA 27.8× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 12
FUTURE (revenue growth)0 · sector 27
PAST (return on equity)25 · sector 49
HEALTH (low debt)100 · sector 94
DIVIDEND (yield)60 · sector 41

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Eli Lilly and Company LLY $1,136 $778.94 −31%
Johnson & Johnson, JNJ $267.20 $169.04 −37%
AbbVie Inc ABBV $263.04 $259.66 −1%
Roche Holding RO CHF 369.80 CHF 306.54 −17%
Merck & Co MRK €124.22 €101.89 −18%
Novartis AG NVS $137.16 $138.70 +1%
Novo Nordisk A/S NOVOB kr 272.60 kr 409.46 +50%
Amgen Inc AMGN $375.65 $413.22 +10%
Gilead Sciences, Inc GILD $146.30 $198.51 +36%
Pfizer Inc PFE $27.55 $20.39 −26%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "HAW PAR CORP LTD Fair Value". https://www.fairvalue-calculator.com/stock/H02

Frequently asked questions

Is HAW PAR CORP LTD (H02) overvalued or undervalued?
As of Sep 19, 2026, our model estimates a fair value of 8.53 SGD versus a price of 13.26 SGD, about −36% upside (overvalued).
What is the fair value of H02?
Our model-based fair value for HAW PAR CORP LTD is 8.53 SGD (as of Sep 19, 2026), built from audited fundamentals. The current price: 13.26 SGD.
What is the quality score of H02?
HAW PAR CORP LTD has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for HAW PAR CORP LTD (H02)?
Our model-based price target is the fair value of 8.53 SGD (as of Sep 19, 2026) from 24 valuation models. Cautious scenario 7.24 SGD, optimistic scenario 10.36 SGD. It is a calculation from audited fundamentals, not an analyst target.
What is the HAW PAR CORP LTD stock forecast for 2026?
Our models put fair value at 8.53 SGD, about −36% upside versus a price of 13.26 SGD (overvalued). Cautious scenario 7.24 SGD, optimistic scenario 10.36 SGD. The calculation is refreshed regularly with new filings.
What is the revenue of HAW PAR CORP LTD (H02)?
HAW PAR CORP LTD reported trailing-twelve-month revenue of about 230M SGD (latest available figure, as of Sep 19, 2026).
Does HAW PAR CORP LTD pay a dividend?
HAW PAR CORP LTD currently shows a dividend yield of about 3.02% relative to its recent price (as of Sep 19, 2026).
What growth is priced into HAW PAR CORP LTD (H02)?
For today's price to be fair in a discounted-cash-flow model, HAW PAR CORP LTD would have to grow free cash flow by +20.4 % per year for five years (discount rate 8.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +15.7 % per year. As of Sep 19, 2026.
What discount rate (WACC) does the fair value of H02 use?
Our models discount HAW PAR CORP LTD at 8.3 %: a base by market capitalisation (mid), damped by beta 0.16, country premium for Singapore. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For HAW PAR CORP LTD that is +20.4 % per year a year over ten years, using the same discount rate (8.3 %) and the same formula as our fair value.
How much growth has HAW PAR CORP LTD (H02) delivered so far?
Over the past 5 years revenue at HAW PAR CORP LTD grew +15.7 % a year. The price currently implies +20.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of HAW PAR CORP LTD (H02) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into HAW PAR CORP LTD (+20.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of HAW PAR CORP LTD (H02)?
The free-cash-flow yield on the price is 1.87 %: that much free cash flow HAW PAR CORP LTD produces per unit of market value. When it exceeds the discount rate of our models (8.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of HAW PAR CORP LTD (H02)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For HAW PAR CORP LTD it is 8.53 SGD per share (as of Sep 19, 2026), against a price of 13.26 SGD. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is HAW PAR CORP LTD stock overvalued or undervalued in 2026?
As of Sep 19, 2026, H02 trades above its calculated fair value: price 13.26 SGD, fair value 8.53 SGD, a gap of about −36% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of H02?
No. The price is what the market pays today (13.26 SGD); the fair value is what the company's own numbers justify (8.53 SGD). For HAW PAR CORP LTD the two are 4.73 SGD per share apart. That gap is exactly why we show both numbers side by side.
How much is HAW PAR CORP LTD worth?
The market values HAW PAR CORP LTD at about 3.5B SGD (market capitalisation, as of Sep 19, 2026). Per share that is 13.26 SGD; our models calculate a fair value of 8.53 SGD per share.
What do the bullish and bearish scenarios say about H02?
Our models span a range for HAW PAR CORP LTD: cautious scenario 7.24 SGD, base 8.53 SGD, optimistic 10.36 SGD per share (as of Sep 19, 2026, price 13.26 SGD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of H02?
HAW PAR CORP LTD trades at a price-to-earnings ratio of 11.1 (as of Sep 19, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 8.53 SGD is built from several models across several years. Other multiples: P/B 0.7, P/S 12.1, EV/EBITDA 27.8.
How solid is the balance sheet of HAW PAR CORP LTD (H02)?
Balance-sheet figures for HAW PAR CORP LTD (as of Sep 19, 2026): return on equity 6.3%, debt of 0.01 per unit of equity. They feed the Quality Score of 70/100, which measures business quality independently of the share price.
How far is H02 from its 52-week high?
HAW PAR CORP LTD trades at 13.26 SGD, about 27% below its 52-week high of 18.06 SGD and 13% above the low of 11.76 SGD (as of Sep 19, 2026). Distance from the high says nothing about value: that is what the fair value of 8.53 SGD is for.
Which stocks are comparable to HAW PAR CORP LTD?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is HAW PAR CORP LTD stock attractive at the current price?
The data as of Sep 19, 2026: price 13.26 SGD, calculated fair value 8.53 SGD (−36%), Quality Score 70/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of H02 calculated?
We run HAW PAR CORP LTD through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 8.53 SGD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.0 % above its aggregate fair value. HAW PAR CORP LTD itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of HAW PAR CORP LTD (H02)?
The closing price on Sep 18, 2026 was 13.26 SGD. Our model-based fair value is 8.53 SGD, about −36% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with HAW PAR CORP LTD right now?
A high-quality business (quality 70/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case (10.36 SGD). The favourable scenario is already priced in.

Key figures of HAW PAR CORP LTD

How large is the market capitalisation of HAW PAR CORP LTD (H02)?
The market capitalisation of HAW PAR CORP LTD is 3.5B SGD (≈ $2.8B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of HAW PAR CORP LTD (H02)?
The price-to-sales ratio of HAW PAR CORP LTD is 12.8 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of HAW PAR CORP LTD (H02)?
Earnings per share at HAW PAR CORP LTD are 1.20 SGD (price ÷ EPS = P/E 11.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of HAW PAR CORP LTD (H02)?
The dividend yield of HAW PAR CORP LTD is 3.0% (payout 33.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of HAW PAR CORP LTD (H02)?
The net margin of HAW PAR CORP LTD is 115% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of HAW PAR CORP LTD (H02)?
The return on equity (ROE) of HAW PAR CORP LTD is 6.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of HAW PAR CORP LTD (H02)?
On an EBIT basis the return on assets of HAW PAR CORP LTD is 1.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of HAW PAR CORP LTD (H02)?
The operating margin of HAW PAR CORP LTD is 32.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at HAW PAR CORP LTD (H02)?
Revenue at HAW PAR CORP LTD is growing −18.2% versus a year earlier (3y avg +8.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at HAW PAR CORP LTD (H02)?
Earnings per share at HAW PAR CORP LTD are growing +14.2% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed

Watch HAW PAR CORP LTD in the live analysis

One click puts HAW PAR CORP LTD on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.